Humanin: A Mitochondria-Encoded Cytoprotective Micropeptide

Research summary. Humanin is a 24-amino-acid micropeptide encoded by a small open reading frame within the mitochondrial 16S ribosomal RNA gene. It was discovered in 2001 by Hashimoto, Niikura, and colleagues working in the laboratory of Ikuo Nishimoto, who identified the peptide in a screen for factors protecting cells from amyloid-β-induced apoptosis [1]. Humanin was one of the founding members of the now-substantial class of mitochondria-derived peptides (MDPs), which has expanded to include MOTS-c, SHLPs (small humanin-like peptides), and others.

Molecular profile

• Sequence: Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Leu-Thr-Ser-Glu-Ile-Asp-Leu-Pro-Val-Lys-Arg-Arg-Ala (MAPRGFSCLLLLTSEIDLPVKRRA)
• Length: 24 residues
• Encoding: Small open reading frame within the mitochondrial 16S rRNA gene (MT-RNR2)
• Class: Mitochondria-derived peptide (MDP)

The peptide is unusual in being encoded by mitochondrial rather than nuclear DNA, joining a small but growing list of bioactive products from the mitochondrial genome beyond the canonical respiratory-chain proteins.

Mechanism of action

Humanin's principal characterised activity is anti-apoptotic protection, particularly against stress-induced apoptosis in vulnerable cell populations:

• BAX/BAK inhibition. Humanin binds to and inhibits Bax (Bcl-2-associated X protein) and Bid/tBid, preventing mitochondrial outer membrane permeabilisation and the downstream caspase activation that drives apoptotic cell death.
• IGFBP-3 binding. Humanin interacts with insulin-like growth factor binding protein 3 (IGFBP-3), with downstream effects on IGF-1 axis signalling and apoptotic regulation.
• Receptor engagement. A heterotrimeric receptor complex composed of CNTFR (ciliary neurotrophic factor receptor), WSX-1, and gp130 has been characterised as a humanin-responsive receptor system, with downstream STAT3 signalling implicated in protective effects.
• Anti-amyloid-β activity. The original context of humanin's discovery — protection against amyloid-β-induced apoptosis — has been characterised at the molecular level, with humanin reported to inhibit Bax-mediated apoptotic signalling triggered by Aβ exposure.

Preclinical research highlights

Alzheimer's disease research. Cell-culture and rodent studies have reported that humanin protects neurons against amyloid-β-induced apoptosis. Astrocytes have been reported as a primary endogenous source of humanin in the CNS. Age-related declines in humanin levels have been hypothesised to contribute to neuronal vulnerability in late-onset neurodegenerative disease.

Excitotoxicity and stroke. Humanin has been reported to attenuate NMDA-induced excitotoxic neuron death and to support neuronal survival following ischaemic insult in animal models.

Cardiac protection. Studies in cardiac ischaemia-reperfusion preparations have reported reduced infarct size and improved myocardial function with humanin administration, attributed to inhibition of cardiomyocyte apoptotic pathways.

Retinal protection. A particularly active area of humanin research involves the retinal pigment epithelium (RPE). Humanin has been reported to reduce oxidative stress in RPE cells and to protect against age-related RPE dysfunction relevant to macular degeneration. RPE cells express a substantial repertoire of humanin-responsive receptors, supporting interest in retinal applications.

Insulin sensitivity and metabolic effects. Humanin and its analogues have been reported to enhance insulin sensitivity and glucose handling in rodent models, with proposed mechanisms involving modulation of hypothalamic feeding circuits and direct effects on metabolic tissue.

IGF-1 axis cross-talk. A distinctive feature of humanin biology is its bidirectional relationship with IGF-1 signalling. Humanin reduces circulating IGF-1 levels in some contexts, while IGF-1 exposure modulates humanin levels. The two peptides interact at the level of IGFBP-3 binding and may produce coordinated effects on apoptosis and metabolic signalling — though the relationship is complex and context-dependent.

Position in the MDP family

Humanin sits among other characterised mitochondria-derived peptides:

• Humanin (24 residues): Anti-apoptotic, neuroprotective, retinal protection
• MOTS-c (16 residues): Encoded in 12S rRNA, primarily metabolic effects, AMPK activation
• SHLP1-6 (small humanin-like peptides): A family of peptides with variable activity profiles, less extensively characterised

Together these molecules constitute a small but conceptually important class of bioactive products from the mitochondrial genome, expanding the conventional view of mitochondrial DNA as encoding only respiratory-chain components.

Current research status

Humanin remains an investigational research peptide. It is not approved as a therapeutic by any major regulatory authority. Engineered humanin analogues with enhanced potency (notably HNG, a glycine-substituted variant ~1000-fold more active in some assays) are widely used as research tools.

Active research applications include:

• Neurodegeneration models (Alzheimer's, prion disease, ALS)
• Retinal degeneration and AMD-relevant research
• Cardiac ischaemia-reperfusion preclinical work
• Insulin sensitivity and metabolic-disease research
• Mechanistic studies of mitochondria-derived peptide biology

Key takeaways for researchers

• Humanin is a 24-amino-acid micropeptide encoded by a small ORF in the mitochondrial 16S rRNA gene.
• It was the founding member of the mitochondria-derived peptide (MDP) class.
• Its principal activity is anti-apoptotic, particularly via Bax/Bid inhibition and a CNTFR/WSX-1/gp130 receptor complex with downstream STAT3 signalling.
• Reported activity spans neurodegeneration, retinal protection, cardiac ischaemia, and metabolic effects.
• It is not an approved therapeutic.

References

1. Hashimoto Y, Niikura T, Tajima H, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ. Proceedings of the National Academy of Sciences USA. 2001;98(11):6336–6341.

---

This article is provided for educational and research purposes only. Humanin is a research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.